Vaccinex Inc (VCNX)

$1.01 -0.05 (-4.72%)
Market Cap 2.76M
Revenue (ttm) 570,000.00
Net Income (ttm) -20.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,552.63%
Debt to Equity Ratio -0.03
Volume 47,806
Avg Vol 128,437
Day's Range N/A - N/A
Shares Out 2.60M
Stochastic %K 7%
Beta 1.10
Analysts Strong Buy
Price Target $7.00

Company Profile

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepin...

Industry: Biotechnology
Sector: Healthcare
Phone: 585 271 2700
Fax: 585 271 2765
Address:
1895 Mount Hope Avenue, Rochester, United States
wjmax
wjmax Apr. 5 at 3:03 PM
$NWBO $VCNX Amazing results can be seen in animal model about the combination of DC vaccine with SEMA4D blockade. A human trial is undergoing which has primary completion time set for April. What would happen when the trial results are out?! Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /​Trastuzumab in Patients w/​ Metastatic HER2+ Breast Cancer https://clinicaltrials.gov/study/NCT05378464
1 · Reply
wjmax
wjmax Apr. 5 at 2:56 PM
$NWBO $VCNX It seems like Merck has been testing the combination of its keytruda with various treatments either complementary to or synergistic with DCVax! $VCNX, an OTC company, is the only one that has SEMA4D blockade. https://clinicaltrials.gov/study/NCT04815720
0 · Reply
wjmax
wjmax Apr. 5 at 2:09 PM
$NWBO $VCNX Absolutely amazing results! https://www.cell.com/cell-reports/fulltext/S2211-1247(26)00128-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124726001282%3Fshowall%3Dtrue
0 · Reply
Tyjelly
Tyjelly Apr. 1 at 4:58 PM
$VCNX if they are truly accumulating there cannot be many shares left.
1 · Reply
Tyjelly
Tyjelly Mar. 30 at 8:01 PM
$VCNX not selling for anything under $400
1 · Reply
WillyT2
WillyT2 Mar. 28 at 5:59 PM
$VCNX To all my VCNX friends and bag holders. I’m still in this, just not much to talk about lately. Take a look at TGL, I think this will explode next week, you can make some money back
2 · Reply
rk39842
rk39842 Mar. 27 at 8:44 PM
$ARTL who is the pump master here? I mean who and why anyone would even bother ...I got used to holding these damn bag ....someday this & $VCNX will be tax write off
0 · Reply
SmallTimer7
SmallTimer7 Mar. 25 at 8:03 PM
$VCNX Merck acquisition news fed into my grok chain: Bottom Line: Encouraging for the oncology deal climate (Merck paying big for early differentiation), which indirectly helps VCNX’s positioning. But it’s not specific progress for pepinemab’s trials or stages—more “good macro tailwind” than direct catalyst. Vaccinex’s science (TME/CTC disruption) aligns with what big pharma is chasing, but execution (cash runway, Phase 2b start, HNSCC readout) remains key. No ROI stripping here; this environment favors survival and eventual exit. Hold steady—watch for HNSCC symposium news or AD trial updates. More catalysts could turn this into real momentum.
0 · Reply
SmallTimer7
SmallTimer7 Mar. 25 at 2:28 PM
$VCNX No shares still and they regurgitated to 60M funding from December on their LinkedIn today
1 · Reply
Tyjelly
Tyjelly Mar. 24 at 8:22 PM
$VCNX no shares traded today.
0 · Reply
Latest News on VCNX
No data available.
wjmax
wjmax Apr. 5 at 3:03 PM
$NWBO $VCNX Amazing results can be seen in animal model about the combination of DC vaccine with SEMA4D blockade. A human trial is undergoing which has primary completion time set for April. What would happen when the trial results are out?! Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /​Trastuzumab in Patients w/​ Metastatic HER2+ Breast Cancer https://clinicaltrials.gov/study/NCT05378464
1 · Reply
wjmax
wjmax Apr. 5 at 2:56 PM
$NWBO $VCNX It seems like Merck has been testing the combination of its keytruda with various treatments either complementary to or synergistic with DCVax! $VCNX, an OTC company, is the only one that has SEMA4D blockade. https://clinicaltrials.gov/study/NCT04815720
0 · Reply
wjmax
wjmax Apr. 5 at 2:09 PM
$NWBO $VCNX Absolutely amazing results! https://www.cell.com/cell-reports/fulltext/S2211-1247(26)00128-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124726001282%3Fshowall%3Dtrue
0 · Reply
Tyjelly
Tyjelly Apr. 1 at 4:58 PM
$VCNX if they are truly accumulating there cannot be many shares left.
1 · Reply
Tyjelly
Tyjelly Mar. 30 at 8:01 PM
$VCNX not selling for anything under $400
1 · Reply
WillyT2
WillyT2 Mar. 28 at 5:59 PM
$VCNX To all my VCNX friends and bag holders. I’m still in this, just not much to talk about lately. Take a look at TGL, I think this will explode next week, you can make some money back
2 · Reply
rk39842
rk39842 Mar. 27 at 8:44 PM
$ARTL who is the pump master here? I mean who and why anyone would even bother ...I got used to holding these damn bag ....someday this & $VCNX will be tax write off
0 · Reply
SmallTimer7
SmallTimer7 Mar. 25 at 8:03 PM
$VCNX Merck acquisition news fed into my grok chain: Bottom Line: Encouraging for the oncology deal climate (Merck paying big for early differentiation), which indirectly helps VCNX’s positioning. But it’s not specific progress for pepinemab’s trials or stages—more “good macro tailwind” than direct catalyst. Vaccinex’s science (TME/CTC disruption) aligns with what big pharma is chasing, but execution (cash runway, Phase 2b start, HNSCC readout) remains key. No ROI stripping here; this environment favors survival and eventual exit. Hold steady—watch for HNSCC symposium news or AD trial updates. More catalysts could turn this into real momentum.
0 · Reply
SmallTimer7
SmallTimer7 Mar. 25 at 2:28 PM
$VCNX No shares still and they regurgitated to 60M funding from December on their LinkedIn today
1 · Reply
Tyjelly
Tyjelly Mar. 24 at 8:22 PM
$VCNX no shares traded today.
0 · Reply
justfacts1
justfacts1 Mar. 24 at 6:41 PM
$VCNX are they alive!
0 · Reply
Projecticarius_theclever
Projecticarius_theclever Mar. 20 at 8:08 PM
$VCNX UK
0 · Reply
colebag
colebag Mar. 20 at 4:51 PM
$VCNX
0 · Reply
St0ckPwn
St0ckPwn Mar. 20 at 3:31 PM
$VCNX I see this is slowly going up 😂 you’re welcome guys this only happens when I sell
1 · Reply
SmallTimer7
SmallTimer7 Mar. 17 at 2:25 PM
$VCNX Bottom line: Solid mechanistic pub keeps momentum alive (onc + neuro). No ROI dilution here—it’s free validation. Insiders still all-in. Hold for the next catalyst (HNSCC symposium or Phase 2b start).
2 · Reply
Javivi33
Javivi33 Mar. 17 at 2:03 PM
$VCNX pepinemab looks efective in Múltiple vectors. Difficult to make a valuation. But usually 1 vector 1000 million. Here?? Múltiple types of cáncer, alzheimer and Who knows. They Will grab us Up from our feet till they get the last share.
0 · Reply
Tyjelly
Tyjelly Mar. 13 at 10:01 PM
$VCNX we’re so fooked
0 · Reply
LionNoRichy
LionNoRichy Mar. 13 at 2:38 PM
$VCNX woahh
0 · Reply
SmallTimer7
SmallTimer7 Mar. 13 at 2:29 PM
$VCNX Another bag dump? Haha
0 · Reply
colebag
colebag Mar. 13 at 2:01 PM
$VCNX Yup there goes the ask of 1.50. No more glimering light, back to endless limbo
0 · Reply
novastrae
novastrae Mar. 11 at 5:09 PM
$VCNX not even published journal news moved the needle , in fact it went backwards 😂
3 · Reply
rk39842
rk39842 Mar. 11 at 4:19 PM
$ARTL $VCNX I guess I should just start a shell company, reserve merger that either of these 2 companies and release million more shares ....there are lot of traders like me who will buy on initial pump ...that's the only cheap way I see to recover what I have lost so far with these 2 companies!!!!
1 · Reply